[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D.
Latorzeff I, et al. Among authors: duberge t.
Cancer Radiother. 2020 Apr;24(2):143-152. doi: 10.1016/j.canrad.2019.06.018. Epub 2020 Feb 11.
Cancer Radiother. 2020.
PMID: 32057646
Review.
French.